A. Braud

High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study.

P. Viens, C. Tarpin, F. Viret, 2005, Anticancer research.

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

F. Bertucci, D. Blaise, P. Viens, 2004, Bone Marrow Transplantation.

Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy

F. Bertucci, P. Viens, C. Arnoulet, 2003, Bone Marrow Transplantation.

Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens

F. Bertucci, P. Viens, C. Chabannon, 2002, Bone Marrow Transplantation.

Cowden disease and Lhermitte Duclos disease, markers of breast carcinoma: report of two patients.

M. Espié, M. Marty, A. de Rocquancourt, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel and Radiotherapy and Pancreatic Cancer

M. Ychou, P. Viens, G. Gravis, 2003, Pancreas.

Cost–effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation

D. Blaise, P. Viens, N. Vey, 2003, Leukemia.

Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation

F. Bertucci, P. Viens, G. Houvenaeghel, 2002, Bone Marrow Transplantation.

Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors.

P. Viens, G. Gravis, C. Tarpin, 2003, Anticancer research.